Verruco-papillary lesions (VPLs) of the oral cavity described in the literature involve a spectrum of conditions
including squamous papilloma, verruca vulgaris, focal epithelial hyperplasia, condyloma, proliferative verrucous
leukoplakia and verrucous carcinoma. A majority of the VPLs are slow growing, benign in nature and have a
viral aetiology. Virus associated benign mucosal outgrowths are not too difficult to diagnose either clinically or
by microscopy. Apart from virus-associated lesions, VPLs harboring malignant potential or behaviour such as
verrucous carcinoma, proliferative verrucous leukoplakia, oral verrucous hyperplasia (OVH), oral papillary
squamous cell carcinoma (PSCC) and oral conventional squamous cell carcinoma with papillary features (CSCC)
need to be further clarified for better understanding of their predictable biologic behavior and appropriate
treatment. Current understanding of potentially malignant VPLs is perplexing and is primarily attributed to
the use of confusing and unsatisfactory terminology. In particular, the condition referred to as oral verrucous
hyperplasia (OVH) poses a major diagnostic challenge. OVH represents a histopathological entity whose clinical
features are not well recognised and is usually clinically indistinguishable from a verrucous carcinoma and a
PSCC or a CSCC. A consensus report published by an expert working group from South Asia as an outcome of
the ‘First Asian Regional Meeting on the Terminology and Criteria for Verruco-papillary Lesions of the Oral
Cavity’ held in Kuala Lumpur, Malaysia, recognised the clinical description of these OVH as a new entity named
‘Exophytic Verrucous Hyperplasia’. Previously described clinical features of OVH such as the ‘blunt’ or ‘sharp’
variants; and the ‘mass’ or ‘plaque’ variants can now collectively fall under this newly described entity. This paper
discusses in detail the application of the standardized criteria guidelines of ‘Exophytic Verrucous Hyperplasia’
as published by the expert group which will enable clinicians and pathologists to uniformly interpret their pool
of OVH cases and facilitate a better understanding of OVH malignant potential.
* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.